Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides healthcare delivery and payment solutions in the United States. The company is headquartered in Arlington, Virginia.
| Revenue (TTM) | $2.10B |
| Gross Profit (TTM) | $361.64M |
| EBITDA | $61.04M |
| Operating Margin | -1.34% |
| Return on Equity | -67.00% |
| Return on Assets | -0.79% |
| Revenue/Share (TTM) | $18.64 |
| Book Value | $3.52 |
| Price-to-Book | 1.38 |
| Price-to-Sales (TTM) | 0.25 |
| EV/Revenue | 0.66 |
| EV/EBITDA | 88.49 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 46.90% |
| Shares Outstanding | $113.06M |
| Float | $94.15M |
| % Insiders | 3.16% |
| % Institutions | 101.55% |
Volatility is currently contracting
Evolent Health, Inc. is awarded a contrarian Buy rating despite extreme indebtedness and recent net losses. EVH trades at a deeply distressed valuation (~0.2x forward sales) due to ~$967m long-term debt and persistent GAAP losses. Management projects >25% revenue growth and adjusted EBITDA ≥$150m in 2027, aiming to improve leverage and capital structure.
Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Evolent Health (EVH) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.1 per share a year ago.
WASHINGTON, Aug. 6, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2026. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate that Evolent is delivering strong growth, profitability and cash flow.
The “Mag Seven” has become the “Bag Seven.” Sharp tech investors are looking elsewhere.
Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.
WASHINGTON, July 8, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before market open, with a conference call to follow at 8 a.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Evolent Health, Inc (EVH) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, EVH's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Evolent Health (EVH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EVH and any ticker you trade — then tracks every position and per-strategy win rate.
